Alkem Laboratories Acquires Equity in Enzene Biosciences

Alkem Laboratories Ltd has acquired 64,02,018 equity shares of its subsidiary, Enzene Biosciences Limited, at an issue price of Rs. 468.60 per share. The total consideration for this acquisition amounts to Rs. 299,99,85,635. The shares were allotted on December 26, 2025, increasing Alkem’s shareholding in Enzene to 99.61%.

The acquisition was conducted on a rights basis and does not fall within the purview of related party transactions. The purpose of acquiring these shares is to meet Enzene’s capital expenditure and working capital requirements. No governmental or regulatory approvals were required for this transaction.

Enzene Biosciences Limited is engaged in the research and development, manufacturing, and out-licensing of biosimilar products. It also provides contract development and manufacturing services for biosimilars and novel biologics. Enzene reported a turnover of INR 363.62 crores for the financial year ending March 31, 2025. The company was incorporated on August 28, 2006, under the Companies Act, 1956.

In the previous financial years, Enzene’s turnover was INR 262.66 crores for 2023-2024 and INR 144.00 crores for 2022-2023. The company operates within India and internationally, focusing on biosimilars and biologics contract manufacturing.

Alkem Laboratories Ltd is a leading pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company focuses on expanding its product portfolio and enhancing its manufacturing capabilities to meet growing market demands. Alkem continues to strengthen its presence in the pharmaceutical industry through strategic acquisitions and investments in its subsidiaries.